Introduction  by Mudge, Gilbert H. & Duggin, Geoffrey G.
The Symposium on Drug Effect on the Kidney
was held in Sydney in October, 1979, under the
sponsorship of the Australian Society of Nephrol-
ogy and the Royal Prince Alfred Hospital. Renal
pharmacology often is tacitly assumed to be almost
synonymous with the pharmacology of diuretic
drugs, for understandable reasons. Certainly these
are the agents most often prescribed because of
their renal site of action. But, in planning the sym-
posium, it was considered desirable to focus on oth-
er types of drugs that act on the kidney. As the final
program evolved, approximately two thirds of the
papers were concerned with various aspects of
nephrotoxicity. This emphasis was readily justified
on two scores: its enormous importance in clinical
medicine and the accelerated pace of interest in re-
cent basic research. The remaining papers were
concerned with a variety of other biochemical,
physiologic, and pharmacologic problems.
Although the nature of clinical drug toxicity is
widely recognized, the magnitude of the problem is
difficult, if not impossible, to define. This applies to
toxicity in general as well as to nephrotoxicity in
particular. Many of the therapeutic problems that
are involved have been covered in the symposium.
These include the use of antibiotics, the chemother-
apy of malignancy, the treatment of mental illness,
the management of hypertension, the use of analge-
sics, the public health implications of over-the-
counter sales, and several aspects of the impact of
environmental pollutants on health.
The mechanisms of drug action vary from one tis-
sue to another. Some of the factors peculiar to the
kidney are discussed in detail and need not be re-
peated here. We mention, however, the recurrent
statement that the kidney's vulnerability to the ad-
verse effects of drugs is related to the exceptionally
high renal blood flow. The concept is correct at one
extreme to the extent that an avascular tissue would
be relatively drug insensitive, and at the other ex-
treme to the extent that there are some drugs, not a
great many, that are completely removed or ex-
tracted by the kidney from the incoming arterial
blood. In this instance, the renal blood flow can be-
come the rate-limiting factor that determines the
amount of drug to which the kidney is exposed.
For most drugs, however, the importance of renal
blood flow involves its relationship to other renal
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mechanisms. The kidney has the capacity to filter
an enormous volume of fluid at the glomerulus.
There is also a large assortment of specific mecha-
nisms for the transport of different drugs across the
tubular epithelium. Both processes can increase the
concentrations of drugs—the former when the rate
of water reabsorption exceeds the rate of drug reab-
sorption, the latter when the transport process itself
delivers the drug either into the tubular fluid or into
the tubular cell. Additional factors must also be
taken into consideration such as binding to plasma
protein, the rate of urine flow, the pH of the urine,
and the presence of analagous compounds that
might influence transport.
A basic tenet of pharmacology is that drug action,
either beneficial or toxic, depends on the concentra-
tion of drug in the neighborhood of receptors. We
say neighborhood" advisedly because often nei-
ther drug concentrations nor locations of receptors
are known with certainty, particularly in the kid-
ney. For a number of drugs, however, these ques-
tions are now being answered in relation to distribu-
tion both along the nephron as well as within the
subcellular organelles.
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